After U.K. health officials declared an impasse over the cost of a Vertex Pharmaceuticals (VRTX) drug, the chief executive of the company urged U.K. Prime Minister Theresa May to reverse the decision, but also questioned the commitment her government has to biotech investment in the country.
In a Friday letter to May, Jeff Leiden maintained Vertex made “the most innovative and best offer in the world” to the National Health Service for the Orkambi cystic fibrosis medicine, but he complained the health agency has shown “no flexibility by adhering to arbitrary value thresholds.”
About the Author Reprints
